Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment

Sally Arai, Jeffrey Margolis, Marianna Zahurak, Viki Anders, Georgia Boyce Vogelsang

Research output: Contribution to journalArticle

Abstract

Treatment of acute graft-versus-host disease (aGVHD) has relied on high-dose steroids, but less than 50% of patients show durable remission. Antithymocyte globulin (ATG) has become a standard salvage therapy. We now report our experience with ATG for the treatment of steroid-refractory GVHD in 69 patients treated from January 1, 1980, to May 1,1999. Patients with GVHD were given an overall grade using standard criteria. Overall responses were similar to those in previously published literature. However, long-term survival for this group of patients was dismal. Of the 69 patients treated with ATG for steroid-refractory GVHD, only 3 (5%) are currently alive. The median survival of these patients by GVHD grade was 4.1 months for grade 2, 3.6 months for grade 3, and 2.7 months for grade 4. The age range of the surviving patients was 3 to 25 years. Only 5% of the deaths were due to relapse, with the remaining deaths due to GVHD, infection, and/or organ failure. In conclusion, ATG treatment can produce objective responses in patients with aGVHD, but these responses do not result in long-term survival. Given the poor survival rates of patients treated with ATG for steroid -refractory GVHD, treatment with ATG as standard therapy should be reconsidered. Patients with steroid-refractory GVHD should be enrolled in clinical study until there are data to support a standard salvage therapy.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Volume8
Issue number3
StatePublished - 2002

Fingerprint

Antilymphocyte Serum
Graft vs Host Disease
Steroids
Therapeutics
Salvage Therapy
Survival
Survival Rate
Recurrence

Keywords

  • Antithymocyte globulin
  • Graft-versus-host disease

ASJC Scopus subject areas

  • Transplantation

Cite this

@article{7d142ab2eedc4dadb1c69365ba20e99a,
title = "Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment",
abstract = "Treatment of acute graft-versus-host disease (aGVHD) has relied on high-dose steroids, but less than 50{\%} of patients show durable remission. Antithymocyte globulin (ATG) has become a standard salvage therapy. We now report our experience with ATG for the treatment of steroid-refractory GVHD in 69 patients treated from January 1, 1980, to May 1,1999. Patients with GVHD were given an overall grade using standard criteria. Overall responses were similar to those in previously published literature. However, long-term survival for this group of patients was dismal. Of the 69 patients treated with ATG for steroid-refractory GVHD, only 3 (5{\%}) are currently alive. The median survival of these patients by GVHD grade was 4.1 months for grade 2, 3.6 months for grade 3, and 2.7 months for grade 4. The age range of the surviving patients was 3 to 25 years. Only 5{\%} of the deaths were due to relapse, with the remaining deaths due to GVHD, infection, and/or organ failure. In conclusion, ATG treatment can produce objective responses in patients with aGVHD, but these responses do not result in long-term survival. Given the poor survival rates of patients treated with ATG for steroid -refractory GVHD, treatment with ATG as standard therapy should be reconsidered. Patients with steroid-refractory GVHD should be enrolled in clinical study until there are data to support a standard salvage therapy.",
keywords = "Antithymocyte globulin, Graft-versus-host disease",
author = "Sally Arai and Jeffrey Margolis and Marianna Zahurak and Viki Anders and Vogelsang, {Georgia Boyce}",
year = "2002",
language = "English (US)",
volume = "8",
pages = "155--160",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment

AU - Arai, Sally

AU - Margolis, Jeffrey

AU - Zahurak, Marianna

AU - Anders, Viki

AU - Vogelsang, Georgia Boyce

PY - 2002

Y1 - 2002

N2 - Treatment of acute graft-versus-host disease (aGVHD) has relied on high-dose steroids, but less than 50% of patients show durable remission. Antithymocyte globulin (ATG) has become a standard salvage therapy. We now report our experience with ATG for the treatment of steroid-refractory GVHD in 69 patients treated from January 1, 1980, to May 1,1999. Patients with GVHD were given an overall grade using standard criteria. Overall responses were similar to those in previously published literature. However, long-term survival for this group of patients was dismal. Of the 69 patients treated with ATG for steroid-refractory GVHD, only 3 (5%) are currently alive. The median survival of these patients by GVHD grade was 4.1 months for grade 2, 3.6 months for grade 3, and 2.7 months for grade 4. The age range of the surviving patients was 3 to 25 years. Only 5% of the deaths were due to relapse, with the remaining deaths due to GVHD, infection, and/or organ failure. In conclusion, ATG treatment can produce objective responses in patients with aGVHD, but these responses do not result in long-term survival. Given the poor survival rates of patients treated with ATG for steroid -refractory GVHD, treatment with ATG as standard therapy should be reconsidered. Patients with steroid-refractory GVHD should be enrolled in clinical study until there are data to support a standard salvage therapy.

AB - Treatment of acute graft-versus-host disease (aGVHD) has relied on high-dose steroids, but less than 50% of patients show durable remission. Antithymocyte globulin (ATG) has become a standard salvage therapy. We now report our experience with ATG for the treatment of steroid-refractory GVHD in 69 patients treated from January 1, 1980, to May 1,1999. Patients with GVHD were given an overall grade using standard criteria. Overall responses were similar to those in previously published literature. However, long-term survival for this group of patients was dismal. Of the 69 patients treated with ATG for steroid-refractory GVHD, only 3 (5%) are currently alive. The median survival of these patients by GVHD grade was 4.1 months for grade 2, 3.6 months for grade 3, and 2.7 months for grade 4. The age range of the surviving patients was 3 to 25 years. Only 5% of the deaths were due to relapse, with the remaining deaths due to GVHD, infection, and/or organ failure. In conclusion, ATG treatment can produce objective responses in patients with aGVHD, but these responses do not result in long-term survival. Given the poor survival rates of patients treated with ATG for steroid -refractory GVHD, treatment with ATG as standard therapy should be reconsidered. Patients with steroid-refractory GVHD should be enrolled in clinical study until there are data to support a standard salvage therapy.

KW - Antithymocyte globulin

KW - Graft-versus-host disease

UR - http://www.scopus.com/inward/record.url?scp=0036210985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036210985&partnerID=8YFLogxK

M3 - Article

C2 - 11939605

AN - SCOPUS:0036210985

VL - 8

SP - 155

EP - 160

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -